Intracranial Aneurysm

目前AI是一个非常优秀的刚毕业的“学生”，它的记忆力、逻辑性和智能程度都非常好，缺乏个性化的临床经验……来源 | 人民日报健康客户端记者 | 邱越4月19日，一场“人机大战”在“中国脑血管病论坛（CFCVD）”上演。“39AI”“豆包”和“Deepseek”三大AI（人工智能）模型和三位临床医生围绕脑梗死、脑出血、颅内动脉瘤三大经典病例，以病例诊断与治疗方案制定为内容进行现场比拼。活动主席、首都医科大学宣武医院神经外科主任张鸿祺在接受人民日报健康客户端记者采访中表示，从这场比赛中可以看出，目前AI是一个非常优秀的刚毕业的“学生”，它的记忆力、逻辑性和智能程度都非常好，缺乏个性化的临床经验，以及对患者本人及其家庭等背景信息的了解。第一个病例是一位经历过两次手术的动脉瘤复杂病例。主持人一声令下，来自河北北方学院附属第一医院神经外科主治医师田齐开始查阅患者病历，工作人员也同步开始给AI模型输入信息。田齐坦言，“第一次跟AI比赛有些紧张。”十几分钟后，田齐和三大AI模型同时提交了诊断结果和治疗建议。三个AI模型的分析结果非常详实，不仅做出了左侧颈内动脉眼段巨大动脉瘤、左眼失明等主要诊断，且根据提交的病历和检查结果给出了全面的进一步检查建议，以及保守治疗、介入治疗、开放手术等各种治疗建议。而田齐则聚焦患者目前最主要的疾病问题，明确给出了搭桥手术的建议。这一建议也获得了现场点评嘉宾哈尔滨医科大学附属第一医院神经外科主任史怀璋的肯定，“针对这样一个复杂病例，机器可能很难绕过这么多‘弯’，直接抓住病人的最主要、最急需解决问题，在这方面，我们医生的优势就凸显了。但AI的表现也超出我的预期，尤其展现出对资料的分析能力，尤其在一些医生可能会忽略的信息方面，可以为医生提供一个很好的补充。”有意思的情况发生在第三个病例的比拼中。针对这位84岁的脑出血病例，三个AI模型都给出了保守治疗或开颅手术的治疗建议，而参赛选手北京丰台右安门医院神经外科张一鸣则明确表示，由于患者高龄，开颅手术风险较大，建议采取穿刺治疗。复旦大学附属华山医院神经外科主任医师吴雪海在点评中表示，“AI是根据诊疗指南给出的开颅手术建议，但并未充分考虑到病人年龄、恢复周期等其他风险因素。”赛后，三位参赛医生都表示，诊断的全面性是AI技术的最大优势，但每位患者的病情都是个体化的。“AI凭借它庞大的数据优势，会给出非常全面的诊断和建议，但患者需要的是医生明确的决策。而且诊疗过程也是一个人文关怀的过程，这是冰冷的机器无法做到的。”田齐说，“我相信在医疗领域，AI只能是医生的助手和工具。”张鸿祺也表示，“目前AI可以扮演医生小助手的角色，帮助医生来完成一些程序性的事务、作出一些提醒等。伴随着AI技术的发展，医生的确迎来了一个非常好的时代，希望AI大模型能快速学习、尽快成长，为临床带来更多的助益。”责编｜亦一 阿泰封面图来源｜视觉中国医疗投诉再引热议：因为开了13元的检查单，患者投诉，医生停职……集体患癌？顶级医院同科室5名护士确诊颅内肿瘤，医院回应后仍疑点重重医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。☟戳这里，更有料！

In a recent Phase2b trial, NicaPlant has proven that it effectively reduces the risk of angiographic and symptomatic cerebral vasospasm after clipping of ruptured cerebral aneurysms. This reduces stroke and costs associated with the treatment of patients with subarachnoid hemorrhage. Also, early clinical outcomes tended to be improved. The next pivotal step on the way of approval of NicaPlant for routine clinical use for patients, whose aneurysms are clipped, is a Phase 3 trial which aims at confirming these benefits. On the path to realizing this pivotal Phase 3 study, our concept to pursue a novel strategy to prevent vasospasm in patients undergoing aneurysm clipping has been frequently challenged by expert opinions stating that treatment of ruptured aneurysms by microsurgical/open means will not be relevant in the near future (´the market for Clipping is dead´). This statement has always been misleading, if not false, given the evidence available in the literature. Yesterday, the final results of the prospective, multicenter randomized ISAT-2 trial were published in the Journal of Neurosurgery. Main authors are Tim E. Darsaut and Jean Raymond from Canada. The International Subarachnoid Aneurysm Trial–2 was a randomized trial comparing surgical versus EVT (endovascular treatment) of ruptured intracranial aneurysms considered for surgical clipping, despite the results of previous randomized controlled trials, and also eligible for EVT. The primary endpoint was death or dependency according to the modified Rankin Scale score (mRS score > 2) at 1 year. Secondary endpoints included 1-year angiographic results and length of hospital stay. The primary hypothesis was that endovascular management would decrease the number of poor outcomes (mRS score > 2). The results of ISAT-2 draw a different view on the future of open microsurgical therapy and can be summarized as follows: Already 1 year after treatment of Subarachnoid Hemorrhage Clipping proves superior to EVT clinical outcome: Clipping = EVT (mRS>2 30% vs 27%) complete aneurysm occlusion: Clipping superior to EVT (80% vs 50%) residual aneurysm: Clipping superior to EVT (20% vs 8%) more retreatment: Clipping superior to EVT (retreatment associated with unfavorable outcome) repeat aneurysm rupture Clipping superior to EVT (1% vs 4% – 80% fatal) Important for future treatment with NIicaPlant Symptomatic vasospasm was more common with surgery, with the number of patients requiring EVT of vasospasm being similar. Thus, cerebral vasospasm in patients undergoing clipping contributes to high and costly therapy intensity levels and unfavorable individual treatment results for patients with subarachnoid hemorrhage. How does this all translate into BIT Pharma´s treatment concept with NicaPlant:

SAN FRANCISCO--( BUSINESS WIRE )--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced significant milestones in its mission to transform healthcare delivery. In 2024, the company forged new partnerships with three of the largest, global pharmaceutical companies in the world, realizing a total of 10 partnerships with leading life science companies. Viz.ai expanded its reach to serve 1,700 hospitals with a broad user base that grew by more than 30% to reach 60,000 healthcare providers in the United States. This rapidly growing footprint, driven by new product innovation and real-world evidence, demonstrates the company’s commitment to increase access to life-saving treatments. “This year has surpassed our expectations as Viz.ai’s footprint in healthcare continued to grow with the majority of the 50 largest healthcare systems in the U.S. adopting our platform,” said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “This reaffirms Viz.ai’s position as the leading, trusted AI-powered platform and our dedication to delivering tools that empower providers, streamline workflows and improve patient outcomes. As we continue to broaden our patient impact with leading life science collaborators and healthcare systems, we look to accelerate better patient care by leveraging AI-driven insights and care coordination in 2025.” In 2024, Viz.ai introduced new products and capabilities to its Viz.ai One™ enterprise platform, which now includes more than 48 clinical AI modules. Key innovations include the introduction of the Viz ICH Plus™ algorithm for automated volumetric assessment and cutting-edge 3D CT angiography functionality, as well as the launch of Viz Connect® for cryptogenic stroke and Viz ACS for acute coronary syndrome. These enhancements further strengthen Viz.ai’s offering in cardiovascular and neurovascular care pathways, enhancing functionality in both acute and non-acute treatment scenarios and underscoring the company’s commitment to transform healthcare through AI-driven solutions. With 24 new clinical studies this year and more than 100 clinical publications and abstracts to date, Viz.ai has continued to demonstrate substantial real-world evidence of the positive impact of its AI-powered care coordination on patient outcomes and economic efficiency. Three studies at the American College of Cardiology Scientific Session 2024 demonstrated the positive impact of Viz.ai’s hypertrophic cardiomyopathy module on suspected disease detection and patient triage for improved care. Another recent study on pulmonary embolism (PE) showed that the Viz PE solution significantly improved time to assessment and time to anticoagulation with a 74% reduction in in-hospital mortality risk. Additionally, six studies presented at the International Stroke Conference (ISC) 2024 showed the real-world impact of Viz.ai on positive outcomes in clinical practice for acute ischemic stroke, cryptogenic stroke, unruptured incidental cerebral aneurysms and brain hemorrhage. Viz.ai formed new partnerships with leading healthcare technology organizations to further scale its impact. At the Radiological Society of North America (RSNA) meeting, Viz.ai announced a collaboration with Microsoft to deliver a comprehensive platform of more than 48 diagnostic imaging AI models seamlessly embedded into clinical workflows. Together, Viz.ai and Microsoft aim to help radiologists create more accurate reports more efficiently, streamline communication to treating physicians, and support care team collaboration for appropriate follow-up and treatment for patients. Viz.ai announced a partnership with Cleerly at the American College of Cardiology meeting (ACC) and a partnership with Addario Lung Cancer Medical Institute at the American Society of Clinical Oncology meeting to advance care across cardiology, oncology and neurology. This past year, Viz.ai was recognized by Fast Company’s 50 Most Innovative Companies list , received the Prix Galien Award for Best Digital Health Solution in Pharma, and earned its second Edison Award for Viz Pulmonary Embolism. Viz.ai CEO Dr Chris Mansi was also featured as one of the 100 most influential people in AI by TIME Magazine . Collectively, these honors reflect the company’s innovation and impact on expanding patient access to life-saving treatments. About Viz.ai Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700 hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One™ is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.